

1 **Within-host virus evolution during the extended treatment of RSV infection with mutagenic**  
2 **drugs**

3  
4 Christopher J. R. Illingworth<sup>1,2,\*†</sup>, Alexandra Y. Kreins<sup>3,4,\*</sup>, Adriana Margarit-Soler<sup>3</sup>, Tim Best<sup>3</sup>,  
5 Patricia Dyal<sup>4</sup>, Giovanna Lucchini<sup>3</sup>, Kanchan Rao<sup>3</sup>, Rachel Williams<sup>4</sup>, Austen Worth<sup>3</sup>, Judith  
6 Breuer<sup>3,4</sup>

7  
8 <sup>1</sup>MRC-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom

9 <sup>2</sup>Department of Applied Mathematics and Theoretical Physics, University of Cambridge,  
10 Cambridge, United Kingdom

11 <sup>3</sup>Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK

12 <sup>4</sup>Infection, Immunity and Inflammation Research and Teaching Department, University College  
13 London, London, UK

14  
15 \*Authors contributed equally

16 †Email: [christopher.illingworth@glasgow.ac.uk](mailto:christopher.illingworth@glasgow.ac.uk)

17  
18 **Abstract**

19  
20 Antiviral drugs causing viral mutagenesis have shown value against a broad range of RNA viruses  
21 causing respiratory illnesses. While drug-induced accumulation of mutations generally decreases  
22 viral fitness, the potential for mutagenesis to generate escape variants is unknown and concerns  
23 have been raised about adaptive evolution promoting drug-resistance. We report prolonged  
24 treatment of a life-threatening RSV infection with a combination of two viral RNA-dependent RNA  
25 polymerase (RdRp) inhibitors, ribavirin and favipiravir, in a child with severe combined  
26 immunodeficiency undergoing haematopoietic stem cell transplantation. Viral deep sequencing

27 of longitudinally collected RSV samples determined that ribavirin caused a 3-fold increase in the  
28 viral mutation rate. There was no synergistic effect upon addition of favipiravir. Viral load remained  
29 unchanged throughout antiviral treatment, but genomic modelling predicted loss of viral fitness  
30 secondary to drug-induced mutagenesis. The viral changes coincided with stabilisation of the  
31 patient's clinical condition. In the absence of viral clearance, adaptive evolution occurred on a  
32 complex fitness landscape, leading to increased population diversity at the haplotype level. The  
33 evolutionary consequences of using mutagenic antiviral drugs are likely to be hard to predict, but  
34 in this example within-host virus evolution under extended treatment with mutagenic drugs  
35 resulted in an overall loss of viral fitness due to deleterious mutations accumulating faster than  
36 could be outweighed by positive selection. These genomic findings occurred in tandem with  
37 evidence of clinical improvement and are potentially associated.

38

## 39 **Introduction**

40

41 Respiratory syncytial virus (RSV) is the primary cause of hospitalization with acute lower  
42 respiratory infection (LRTI) among children, with approximately 3.2 million hospitalisations  
43 worldwide in 2015 (Shi et al., 2017). Public health measures taken during the COVID-19  
44 pandemic have reduced the incidence of RSV infection (Britton et al., 2020; van Summeren et al.,  
45 2021), but concerns remain that this reduction of cases may have led to the accumulation of an  
46 'immunity debt' (Hatter et al., 2021), generating the potential for a future RSV epidemic of  
47 increased severity. There currently is no licensed vaccine against RSV, despite candidates  
48 making it to Phase 3 clinical trials (Ginsburg and Srikantiah, 2021; Madhi et al., 2020). Monoclonal  
49 antibodies have been used for so-called passive immunisation and have shown some potential  
50 to reduce hospitalisation of premature infants predisposed to cardio-respiratory conditions (Morris  
51 et al., 2009; O'Brien et al., 2015), with palivizumab being licensed for use (Mejias and Ramilo,  
52 2008; Wegzyn et al., 2014). Although no randomised trials have been conducted, palivizumab

53 prophylaxis has been recommended in immunosuppressed patients below the age of two (Hirsch  
54 et al., 2013). It is recognised that vulnerable patients who are at risk of life-threatening respiratory  
55 RSV infections also urgently require access to effective antiviral treatments. For example, RSV+  
56 LRTIs are associated with 30% excess mortality in paediatric recipients of haematopoietic stem  
57 cell transplantation (HSCT) (Adams et al., 1999). For this reason it has been recommended to  
58 delay HSCT to allow for LTRI treatment, most commonly with one antiviral, ribavirin, in order to  
59 reduce HSCT-related mortality (Ottaviano et al., 2020).

60

61 Ribavirin is licensed for treatment of RSV infection in children with severe bronchiolitis especially  
62 when they have other underlying illness (Hall et al., 1983; Turner et al., 2014), and has  
63 successfully been used for pre-emptive treatment of RSV infections in these patients (Adams et  
64 al., 1999; Sparrelid et al., 1997). However, its use has been limited by its cost and by concerns  
65 around drug toxicity (Domachowske et al., 2021), and its efficacy as a treatment for established  
66 RSV infection, especially in immunocompromised patients, has not been established. The drug  
67 is an inhibitor of the RNA dependent RNA polymerase (RdRp) of RNA viruses, such as RSV,  
68 inducing C to U and G to A mutations in the viral genome during replication (Vo et al., 2003).  
69 RdRp inhibitors have the potential for broad-spectrum antiviral activity and have been repurposed  
70 for use against a growing number of RNA viruses. Favipiravir, another RdRp inhibitor, has been  
71 licensed in Japan for the treatment of influenza and its mutagenic effect has been demonstrated  
72 with accumulation of signature C to U and G to A mutations (Goldhill et al., 2019). Favipiravir  
73 treatment efficacy against influenza has not convincingly been demonstrated in trials (Furuta et  
74 al., 2017; Hayden et al., 2022; Wang et al., 2020a), but good outcomes have been reported for  
75 combination therapy (Wang et al., 2020b). For example, we previously reported the successful  
76 use of favipiravir in combination with zanamivir, a nucleoside inhibitor, against chronic influenza  
77 B infection in an immunocompromised child (Lumby et al., 2020b). This illustrates that RdRp

78 inhibitors can be repurposed on a compassionate basis as a bridging therapy to corrective cellular  
79 therapy in immunodeficient patients with life-threatening RNA virus infections.

80

81 Further interest in studying mutagenic drugs has arisen during the SARS-CoV-2 pandemic (Brown  
82 et al., 2021). Animal studies showed that favipiravir-induced mutagenesis resulted in loss of  
83 SARS-CoV-2 infectivity (Kaptein et al., 2020). Combination treatment with molnupiravir, another  
84 RdRp inhibitor which induces viral mutagenesis, further amplified this (Abdelnabi et al., 2021).  
85 Molnupiravir has been shown to reduce the risk of hospitalisation or death if given early in SARS-  
86 CoV-2 infection (Gordon et al., 2021; Jayk Bernal et al., 2022; Kabinger et al., 2021), but concerns  
87 have been raised about the potential for mutagenesis to have harmful side-effects. Negative  
88 outcomes could include the induction of mutations in the cells of the person treated (Swanstrom  
89 and Schinazi, 2022), or the promotion of antiviral resistance, such as that observed to favipiravir  
90 in influenza (Goldhill et al., 2018). The evolution of SARS-CoV-2 in immunocompromised hosts  
91 in some ways reflects patterns seen in the emergence of novel viral variants (Harari et al., 2022);  
92 if antivirals promoted harmful patterns of evolution and were disproportionately used among this  
93 cohort that might have global consequences. Before widespread repurposing of RdRp inhibitors,  
94 these concerns need to be addressed.

95

96 We here report treatment outcomes for one paediatric patient with severe combined  
97 immunodeficiency (SCID) and RSV pneumonitis. Before proceeding with HSCT, the patient was  
98 treated with ribavirin, initially in combination with nitazoxanide, which has broad spectrum antiviral  
99 effects against RNA viruses (Blum et al., 2021; Jasenosky et al., 2019), and subsequently in  
100 combination with favipiravir, for which *in vitro* activity specifically against RSV has been reported  
101 (Furuta et al., 2002). The combination of ribavirin and favipiravir has been shown to be synergistic  
102 against influenza *in vitro* through distinct modes of action on its polymerase (Vanderlinden et al.,  
103 2016). In contrast to short trial protocols for favipiravir and/or molnupiravir in patients with RNA

104 virus infections, including influenza, ebola and SARS-CoV-2 (Brown et al., 2021; Guedj et al.,  
105 2018; Hayden et al., 2022; Jayk Bernal et al., 2022), antiviral treatment in this SCID patient was  
106 administered over an extended period of 2 months during which time the patient received a cord  
107 blood HSCT from a matched unrelated donor. While the patient's respiratory function improved  
108 during the antiviral treatment, she did not clear the infection. Taking advantage of the persistent  
109 viral load (VL) during prolonged antiviral treatment in this patient, we used viral genome  
110 sequencing data alongside population genetic modelling to investigate the impact of drug-induced  
111 mutagenesis on the RSV population. We investigated how mutagenic drugs shaped the viral  
112 population, taking a genomic perspective on the question of whether drug treatment contributed  
113 to clinical improvement.

114

## 115 **Results**

116

### 117 *Treatment of a RSV+ LRTI with RdRp inhibitors in a SCID patient awaiting HSCT*

118

119 The patient under investigation was diagnosed during infancy with T-B+NK+SCID due to IL-7Ra  
120 deficiency following recurrent upper respiratory tract infections. Two months following diagnosis  
121 she underwent a first HSCT procedure. She displayed early donor engraftment, but this was not  
122 sustained over time with a progressive decrease in donor chimerism. RSV was first detected in  
123 the nasopharyngeal aspirate (NPA) 6 months after transplantation with a Ct of 22 and continued  
124 to be persistently detected in repeat NPAs. The patient also developed adenoviraemia and was  
125 referred for a second HSCT procedure. In order to reduce the risk of post-HSCT mortality in the  
126 context of an RSV+ LRTI, treatment was initiated with nebulised ribavirin (6g daily) in combination  
127 with nitazoxanide (200mg 12-hourly), and weekly intravenous immunoglobulin therapy. After 4  
128 weeks of this treatment regimen, there was no VL reduction (Figure 1). Nitazoxanide was  
129 discontinued and favipiravir (200mg 8-hourly) was started in addition to ribavirin. VL remained

130 unchanged (Figure 1). 12 days later she underwent a second HSCT procedure with cord blood  
131 stem cells from a matched unrelated donor; for the purposes of our study we denote the date of  
132 this transplant as day 0. From a respiratory point of view, she remained asymptomatic despite  
133 receiving reduced intensity conditioning with targeted busulfan and serotherapy with ATG pre-  
134 HSCT, as well as immunosuppression with ciclosporin and mycophenolate mofetil for graft-  
135 versus-host-disease (GVHD) prophylaxis post-HSCT. Favipiravir was discontinued 18 days after  
136 HSCT. Ribavirin, which after HSCT was changed from inhalation to oral administration (50mg 8-  
137 hourly), was stopped 11 days later. One month after this second HSCT, mixed donor chimerism  
138 was first detected in whole blood and granulocytes, in absence of lymphoid engraftment. Donor  
139 chimerism in the lymphoid lineages increased with progressive reduction and subsequent  
140 cessation of the immunosuppressive GVHD prophylaxis. As of 6 months post-HSCT the patient  
141 displayed improving immune reconstitution with full donor engraftment and RSV was no longer  
142 detected in her NPA (Figure 1).

143

144 In summary, we report clinical stabilisation in an immunodeficient patient with RSV+ LRTI  
145 undergoing HSCT during antiviral treatment with ribavirin in combination with nitazoxanide or  
146 favipiravir, without viral clearance. Notwithstanding the day-to-day variability of Ct values in NPA  
147 samples, VL overall remained unchanged throughout the period of treatment, with no apparent  
148 impact by any of the three drugs used.

149

150 *Genomic consequences of treatment with RdRp inhibitors*

151

152 Next-generation sequencing was performed for RSV isolated from 10 NPA samples, including 3  
153 samples collected prior to treatment initiation, 2 collected during the initial treatment regimen with  
154 ribavirin and nitazoxanide, 4 during treatment with ribavirin and favipiravir, and 1 during  
155 subsequent treatment with ribavirin alone (Figure 2). The results showed substantially increased

156 mutational load in the viral population during treatment despite no fall in VL. Mutational load, equal  
157 to the sum of minor allele frequencies across the genome (Lumby et al., 2020a), describes the  
158 size of the burden carried by viruses resulting from deleterious mutations in the genome, and was  
159 calculated for each sample. Fitting a model to these data suggested that treatment with ribavirin  
160 led to a roughly three-fold increase in the viral mutation rate (Figure 2A); a more complex model  
161 which allowed for a distinct mutation rate upon the addition of favipiravir did not give a significantly  
162 better fit to the data (Figure 2B). Our model of mutational load makes the assumption of a large  
163 effective population size for the virus (Lumby et al., 2020a); an analysis of changes in the viral  
164 population over time found negligible signal of directed evolutionary change in the viral population,  
165 compatible with a slow rate of genetic drift and therefore with this assumption (Figure 2S1).

166

167 Changes in the mutational spectra of the viral population further confirmed the association of  
168 ribavirin with increased mutagenesis. C to U mutations increased during treatment, comprising a  
169 mean of 10.2% of mutational load in the first three samples, but a mean of 20.8% of load in the  
170 last three samples collected. Similarly, G to A mutations increased from a mean of 6.9% of  
171 mutational load in the first three samples collected to a mean of 11.4% across the last three  
172 samples (Figure 3).

173

#### 174 *Fitness costs of viral mutagenesis*

175

176 While treatment did not clear viral infection, the inference of a change in the viral mutation rate  
177 suggests that ribavirin may have nonetheless reduced viral fitness, potentially contributing to the  
178 relatively benign clinical course of RSV infection in this patient undergoing HSCT. An increased  
179 mutation rate leads to each virus carrying an increased number of deleterious mutations, which  
180 inevitably decreases the fitness of the viral population. At the same time, a reduction in viral  
181 fitness may not be accompanied by a large decrease in VL, dependent upon the initial fecundity

182 of the virus. Viral fecundity describes the mean number of cells that will be infected by the viruses  
183 produced by a single infected cell: If a reduction in fitness does not cause this statistic to fall below  
184 one, the viral population will not die out (Bull et al., 2007).

185

186 The precise decline in fitness in the RSV population was difficult to quantify, with our model  
187 containing some redundancy dependent upon the generation time of the viral population (Figure  
188 4A). Assuming a generation time of between 6 and 48 hours (Baccam et al., 2006; Perelson et  
189 al., 1996) we calculated that ribavirin caused between a 38% and a 98% decrease in viral fitness,  
190 a longer generation time leading to a greater loss of fitness (Figure 4B, Figure 4S1). Across  
191 realistic potential values for viral fecundity prior to treatment (Baccam et al., 2006), and under a  
192 simple birth-death model of replication, such reductions in fitness are compatible with a failure to  
193 clear viral infection (Figure 4C,D). Given a long generation time, even a high pre-treatment  
194 fecundity would have been overcome by the resultant loss of fitness. However, at shorter  
195 generation times fitness may be lost without causing an observable signal in the viral load. The  
196 observed failure to clear viral infection suggests a generation time for RSV of less than 40 hours,  
197 but without further knowledge of the virus we are unable to conclude more than this.

198

### 199 *Limited adaptive evolution despite mutagenesis*

200

201 We considered adaptive evolution within the viral population by studying variants observed at  
202 higher frequencies. Among 79 genetic variants observed at frequencies in excess of 5% in at  
203 least two samples (Supplementary Table 1), seven were identified as being potentially influenced  
204 by selection (Figure 5A). Of these, five were non-synonymous and two synonymous.  
205 Correlations between the frequencies of some of these variants were consistent with genetic  
206 hitchhiking (Figure 5S1). None of the potentially selected variants were associated with



207 transcription, suggesting that they are unlikely to have influenced the interaction between RSV  
208 and either ribavirin or favipiravir.

209

210 Of the seven variants, the substitution F168Y in the attachment glycoprotein G is of particular  
211 interest. This variant arises in the central conserved region of G (McLellan et al., 2013); structural  
212 evidence showing the binding of this region by a neutralising antibody (Jones et al., 2018)  
213 highlights that the F168Y substitution would introduce a hydroxyl group into the binding interface  
214 (Figure 5S2), potentially leading to host immune escape. This could constitute a functional  
215 advantage for RSV. Of the other variants, the K272E substitution in the fusion glycoprotein has  
216 been identified as conferring resistance to the monoclonal antibody palivizumab in an animal  
217 system, the substitution being sited at the binding interface with this antibody (Swanson et al.,  
218 2011; Zhao et al., 2004). At the time of infection, the patient was receiving monthly palivizumab  
219 prophylaxis, which had been approved until the end of the RSV season. Upon cessation of  
220 palivizumab, the frequency of this variant decreased over time within the population, suggesting  
221 reversion to the population-wide consensus.

222

223 The escape of viruses from the deleterious effects of mutagenesis could occur either through the  
224 generation of strongly beneficial single mutations, or through the generation of high fitness  
225 combinations of mutations. An assessment of fitness at the level of viral haplotypes showed a  
226 slow process of within-host evolution, with minor gains in viral fitness. A process of haplotype  
227 reconstruction conducted at the seven potentially selected sites suggested that viral diversity at  
228 these sites could be explained in terms of twelve underlying viral haplotypes (Figure 5S3). Of  
229 note, haplotypes containing the F168Y substitution (having an A at the third nucleotide position)  
230 appear at higher frequencies following the use of ribavirin. However, these haplotypes were not  
231 inferred to have substantially higher fitness than other viral sequences. A second reconstruction,  
232 in which haplotype frequencies were constrained to follow an underlying evolutionary model,

233 suggested that the fittest observed haplotype, which contained the L43S and F168Y substitutions  
234 in G, and the K1753N substitution in L, had a fitness just 26% greater than the mean fitness of  
235 the initial population, and just 5% greater than the mean fitness of the population at the time of  
236 the last sample (Figure 5B,C). Rather than a simple pattern of the virus gaining successive  
237 beneficial mutations, adaptation was multi-directional, with the haplotypes that comprised the final  
238 population (5, 8, 10, and 11) occurring in distinct parts of genotype space. In summary, despite  
239 prolonged treatment with effective mutagenic drugs, a raised mutation rate did not lead to the  
240 emergence of highly beneficial escape mutations.

241

242 *Adaptive evolution did not overcome the loss of fitness caused by mutagenesis*

243

244 Adaptive evolution and the accumulation of mutational load occurred in parallel, with competition  
245 between haplotypes occurring while each haplotype gained deleterious mutations through an  
246 increased rate of viral mutation. Combining models showed that even under conservative  
247 assumptions the gain in viral fitness through adaptive evolution fell short of the corresponding  
248 loss of fitness acquired through mutational load (Figure 6). Within our reconstruction the different  
249 components of our model have differing complexity. Once the mutation rate is altered, under our  
250 model the loss of fitness due to viral mutagenesis is fixed. By contrast, the complexity of the  
251 landscape of viral adaptation leads to less uniform gains via adaptive evolution over time.  
252 Nevertheless, in this case of RSV infection, the costs of mutational load outweighed the benefits  
253 of adaptive evolution. Extended treatment with an effective mutagenic drug did not lead to the  
254 generation of beneficial variants sufficient to escape the effects of mutational load.

255

256 **Discussion**

257

258 We have here described a case of long-term RSV infection in a severely immunocompromised  
259 patient, in whom a benign clinical course followed HSCT until eventual clearance of virus occurred  
260 with donor T-cell engraftment and reconstitution of T-cell immunity. During the course of infection  
261 the patient received extended treatment with the mutagenic antiviral drugs ribavirin and favipiravir.  
262 Analysis of changes in viral genome sequence data over time provided insights into the  
263 evolutionary response of the viral population to treatment, confirming a loss of fitness that may  
264 have contributed to containment of the RSV infection until lymphocyte recovery. Our results have  
265 further-reaching implications for our understanding of mutagenic drugs as an approach to treating  
266 RNA-viral infection.

267  
268 Data describing mutational load and mutational spectra showed that, while treatment did not clear  
269 viral infection, ribavirin reduced the fitness of the viral population via an increase in the mutation  
270 rate. Beneficial effects of mutagenic drugs in the absence of viral clearance have been observed  
271 in the treatment of persistent norovirus infection with favipiravir (Ruis et al., 2018). The clearance  
272 of infection is therefore not a necessary condition for treatment to be of clinical value, albeit that  
273 further work would be required to establish the general clinical benefit of antiviral therapies short  
274 of viral clearance. Where ribavirin was responsible for a change in viral mutation rate, favipiravir  
275 did not confer a significant additional benefit, with insufficient dosing being one possible  
276 explanation (Franco et al., 2022).

277  
278 Our approach to quantifying evolutionary changes in the viral population contains multiple  
279 simplifications, working under the assumptions of a large population size and a simple population  
280 structure. In viral populations where extensive polymorphism separated viral subpopulations,  
281 more nuanced approaches to quantifying mutational load would likely be required (Raghwani et  
282 al., 2016). Measurements of viral fitness were also based on an approximation, splitting the  
283 fitness contributions from many hundreds of (presumed deleterious) mutations all across the

284 genome from an adaptive contribution, arising from changes in composition that were  
285 characterised in terms of a few high-frequency variants. Our approach builds on previous models  
286 of virus evolution, whereby beneficial mutations compete with one another, and arise on a  
287 background of neutral and deleterious mutations (Illingworth and Mustonen, 2012; Koelle and  
288 Rasmussen, 2015; Schiffels et al., 2011). A key limitation in our modelling approach is that we  
289 were not able to characterise with precision the fitness effects of deleterious mutations. These  
290 effects are minimised at shorter viral generation times; our lower bound of 6 hours was based on  
291 previous work characterising the time from infection to the first release of viral particles from a cell  
292 during *in vitro* influenza infection (Baccam et al., 2006). Further work on within-host RSV  
293 dynamics could lead to a greater potential for evolutionary inference.

294

295 A modelling limitation to which our results are robust is the exclusion in our model of the possibility  
296 of viral compartmentalisation (Kemp et al., 2021; Sobel Leonard et al., 2017). In inferring  
297 haplotype-level fitnesses we assume a well-mixed population, with changes in viral composition  
298 occurring through competition between variants. In a case of compartmentalisation, the potential  
299 would exist for the changes we observed to have arisen in distinct parts of the airway, with a non-  
300 adaptive process of physical separation and genetic drift explaining the changes in genetic  
301 composition. In this sense, our inference of adaptive evolution is a maximal one, describing the  
302 extent of adaptation if adaptation is the sole driver of population-level change.

303

304 Different aspects of our findings are more or less generalisable to other cases of RSV infection,  
305 to other respiratory viruses and other mutagenic drugs. Under the assumption of a large  
306 population a change in viral mutation rate brought about by a specific dose of drug will lead to a  
307 consistent drop in viral fitness. Intrinsic viral fecundity may differ between patients due to  
308 differences in individualised immune responses, but the extent to which a drug interferes with  
309 replication is likely to remain constant between hosts. By contrast, changes occurring through

310 adaptive evolution are not easily predictable, being dependent upon the precise fitness landscape  
311 (de Visser and Krug, 2014) of the genotypes close to that of the virus which founded infection.  
312 Our study of a single case shows limited viral adaptation relative to the costs imposed by  
313 mutagenesis. However, even multi-case studies face limitations. The within-host fitness  
314 landscapes of viruses can be complex and highly epistatic (Illingworth, 2015), such that even  
315 detailed characterisation of part of the genotypic space of a virus may not be informative for  
316 drawing more general conclusions.

317

318 Progress in understanding the relationship between mutagenic therapies and virus adaptation  
319 therefore remains a challenge. Mutagenesis is likely not to have a great effect where a beneficial  
320 genotype is accessible by a single mutation; the generically high mutation rate and large  
321 population sizes of RNA viruses will mean that such genotypes are created deterministically.  
322 However, mutagenesis may favour the creation of evolutionarily more distant genotypes that  
323 would otherwise not be accessible to the virus. Further, the generation of variants favoured for  
324 within-host adaptation is less of a problem if the same variants are not favoured for viral  
325 transmission (Harari et al., 2022; Lumby et al., 2018). Systematic study of within-host evolution  
326 considering multiple hosts may in future identify undesirable patterns of evolution that are  
327 promoted by antiviral mutagenesis. However, where a drug has been proven to improve short-  
328 term clinical outcomes, the evidential barrier for ceasing the use of that drug should be high.

329

330

## 331 **Methods**

332

333 *Collection of sequence data*

334

335 The Drugs and Therapeutics Committee at Great Ormond Street Hospital for Children approved  
336 antiviral treatment with ribavirin, nitazoxanide and favipiravir in this patient. Repeat NPAs were  
337 obtained for clinical monitoring of the viral load through polymerase chain reaction (PCR). After  
338 securing informed consent, residual viral DNA samples were collected for deep sequencing,  
339 being sequenced using the SureSelect<sup>XT</sup> targeted enrichment method. Sequencing libraries  
340 were prepared using the SureSelect<sup>XT</sup> low input protocol and sequenced on an Illumina MiSeq.  
341 Accompanying clinical data was retrieved from the electronic patient record and anonymised.

342

#### 343 *Processing of sequence data*

344

345 Short read data were aligned using bwa (Li and Durbin, 2010). The SAMFIRE software package  
346 was used to filter short read data, and call single- and multi-nucleotide variants from the data  
347 (Illingworth, 2016).

348

#### 349 *Mutational load*

350

351 The total mutational load was calculated as a sum of filtered variant frequencies. We note that  
352 the variant frequencies we consider in our model are very small, with the vast majority being  
353 observed at frequencies less than 1%. To this extent we carried out a filtering process, described  
354 in a previous publication (Lumby et al., 2020a), that estimates the probability of a variant of given  
355 frequency arising as the result of sequencing error; these probabilities were derived using repeat  
356 sequencing of HCV populations using the same sequencing protocol used for the data described  
357 in this study (Depledge et al., 2011).

358

359 The filtering process was conducted using a mean approach. Considering the frequency of the  
360 non-consensus nucleotide c at locus l in the genome, denoted  $q_{lc}$ , we assigned the frequency-  
361 dependent probability  $p(q)$  that the variant is a false positive, defining the filtered allele frequency

362

$$363 \hat{q}_{lc} = p(q_{lc})q_{lc}$$

364

365 The mutational load was then calculated as

366

$$367 L = \sum_{l=1}^G \sum_{c=1}^3 \hat{q}_{lc}$$

368

369 Where the sums were calculated over the length of the genome and the minority allele  
370 frequencies at each locus.

371

372 *Evolutionary model of mutational load*

373

374 In a large and initially homogeneous population, mutational load increases to equilibrium  
375 according to the equation

376

$$377 L(t) = \frac{U}{s} (1 - e^{-st})$$

378

379 where U is the mutation rate per genome per generation, s is a constant describing the magnitude  
380 of selection against a variant, and t is time in generations (Haldane, 1937). We modified this  
381 equation to describe changes in the viral mutation rate, and variation in the magnitude of selection  
382 acting against a deleterious variant.

383

384 We modelled the change in mutational load assuming that the population begins in a situation of  
385 mutation selection balance with mutation rate  $U_0$  and that at specified times  $T_i$  the mutation rate  
386 changes so that between time  $T_i$  and  $T_{i+1}$  the mutation rate per genome per generation is equal  
387 to  $U_i$ . We further assumed that the virus has a generation time of  $g$  days.

388

389 Under these circumstances, we have an estimator for the total mutational load given a constant  
390 magnitude of selection against each variant

391

$$392 \quad L(t) = \begin{cases} \frac{U_0}{s} & t \leq T_1 \\ \frac{U_i}{s} \left(1 + p_i e^{-\frac{s}{g}(t+o_i)}\right) & T_i < t \leq T_{i+1} \end{cases}$$

393

394 In this equation the value  $o_i$  is an offset term, ensuring continuity wherever the mutation rate  
395 changes. This was calculated in an iterative manner.

396

$$397 \quad o_i = \begin{cases} -\frac{g \log\left(1 - \frac{\hat{q}(T_i)s}{U_i}\right)}{s} - T_i & \frac{\hat{q}(T_i)s}{U_i} < 1 \\ -\frac{g \log\left(\frac{\hat{q}(T_i)s}{U_i} - 1\right)}{s} - T_i & \frac{\hat{q}(T_i)s}{U_i} > 1 \\ -T_i & \frac{\hat{q}(T_i)s}{U_i} = 1 \end{cases}$$

398

399 The value  $p_i$  controls whether the mutational load is increasing or decreasing to its new equilibrium  
400 value and was similarly calculated in an iterative manner.

401



402

$$p_i = \begin{cases} -1 & \frac{\hat{q}(T_i)s}{U_i} < 1 \\ 1 & \frac{\hat{q}(T_i)s}{U_i} > 1 \\ 0 & \frac{\hat{q}(T_i)s}{U_i} = 1 \end{cases}$$

403

404

405 Our model contains some redundancy in so far as fixing the generation time  $g$  does not reduce  
406 the space of possible outcomes. We made the assumption that the generation time was between  
407 6 hours, modelling the first release of influenza viruses from an infected cell (Baccam et al., 2006)  
408 and 48 hours, modelling HIV (Perelson et al., 1996). Optimal values of  $s$  and  $U_i$  were inferred for  
409 values of  $g$  within this range.

410

411 A preliminary optimisation of these parameters was conducted using a least squares model to fit  
412 the modelled and observed values for mutational load, before optimising the variance parameter  
413  $\sigma$  to calculate the maximum likelihood.

414

415

$$L = \sum_t \log \left( \frac{1}{\sigma\sqrt{2\pi}} e^{-\frac{1}{2} \left( \frac{\hat{L}(t) - L(t)}{\sigma} \right)^2} \right)$$

416

417 Having calculated likelihoods for models with and without changes in the mutation rate  
418 corresponding to the use of favipiravir, we compared models using the Bayesian Information  
419 Criterion (BIC).

420

421 *Calculation of changes in viral fitness due to mutational load*

422

423 We used a variant of a Wright-Fisher simulation to model changes in the fitness of the viral  
424 population over time. We divide the viral population into classes according to the number of  
425 mutations in each virus. Then the value  $x_m(t)$  describes the fraction of viruses in class  $m$ , and  
426 therefore having  $m$  mutations, after  $t$  generations.

427

428 We initialised a population in which  $x_0(0)$  was equal to 1. In each generation mutation was  
429 modelled as a Poisson process, so that

430

431 
$$x'_m(t) = \left(1 - \sum_{k=1}^{\infty} \frac{U^k e^{-U}}{k!}\right) q_m(t) + \sum_{k=1}^m x_{m-k}(t) \frac{U^k e^{-U}}{k!}$$

432

433 Following this selection was modelled, whereby

434

435 
$$x_m(t+1) = \frac{x'_m(t) s^m}{\sum_{m=0}^{\infty} x_m(t) s^m}$$

436

437 In this system the mutational load in the population was calculated as

438

439 
$$L(t) = \sum_m m q_m(t)$$

440

441 Given a model of changes in the viral mutation rate fitted to the data, we ran this simulation to  
442 numerical convergence with the mutation rate  $U=u_0$ , and with the parameter  $s$  inferred from the  
443 model. Denoting the time  $t=T$  as the point at which treatment commenced, we altered  $U$  so that  
444  $U=u_1$  for all  $t \geq T$ . The fitness of the population at time  $t$  was calculated as

445

446

$$w(t) = \sum_{m=0}^{\infty} x_m(t) s^m$$

447

448 For the purpose of drawing figures linear interpolation was used to convert the statistics  $L(t)$  and  
449  $w(t)$  from values expressed in generations to values expressed each day.

450

451 *Total evolutionary distance*

452

453 The total evolutionary distance between samples was calculated as described in an earlier  
454 publication (Lumby et al., 2020a). At position  $l$  in the genome we define the vector  $q_l(t)$  as the  
455 vector of the frequencies of the nucleotides A, C, G, and U. Given samples collected at times  $t_1$   
456 and  $t_2$  we define the locus-specific distance  $d$  as a generalisation of the Hamming distance:

457

458

$$d(q_l(t_1), q_l(t_2)) = \frac{1}{2} \sum_{c \in \{A, C, G, U\}} |q_{lc}(t_1) - q_{lc}(t_2)|$$

459

460 Summing these values across the genome we then calculate the total evolutionary distance

461

462

$$D(q(t_1), q(t_2)) = \sum_l d(q_l(t_1), q_l(t_2))$$

463

464 This statistic was used to evaluate the rate of evolution of the viral population, comparing how  
465 changes in  $D$  varied given greater or lesser amounts of differences between the times at which  
466 samples were collected.

467

468 *Birth-death model*

469

470 A simple birth-death model was used to evaluate the potential effects of mutagenic drugs upon  
471 a viral population. Our model was described with the equation

472

$$473 \quad \frac{dV}{dt} = \left( r_G(t) f \left( \frac{C - V}{C} \right) - d \right) V$$

474

475 Where  $V$  is the size of the viral population,  $f$  is the pre-treatment viral fecundity,  $r_G(t)$  is the  
476 reduction in fitness caused by the drug at time  $t$  conditional upon a generation time of  $G$  hours,  
477  $d$  is the death rate of the virus, and  $C$  is the carrying capacity of the system. The values  $C=10^7$   
478 and  $d=1$  were chosen in this case.

479

480 *Identification of potentially selected variants*

481

482 The SAMFIRE software package was used to identify potentially selected single variants in the  
483 population. Variant frequencies  $q(t)$  were identified for single nucleotide variants that reached a  
484 minor allele frequency of at least 5% in at least two samples from the population. As  
485 implemented here, this method three deterministic models of allele frequency change to the  
486 data.

487

488 1. Neutral evolution:

489

$$490 \quad \hat{q}(t) = q$$

491

492 for some constant parameter  $q$ .

493

494 2. Constant selection:

495

496 
$$\hat{q}(t) = \frac{q(0)e^{st}}{1 - q(0) + q(0)e^{st}}$$

497

498 for some constant parameters  $q(0)$  and  $s$ .

499

500 3. Time-dependent selection:

501

502 
$$\hat{q}(t) = q(t)$$

503

504 This latter model is equivalent to one in which selection is allowed to change in an  
505 unconstrained manner in between measurements of allele frequency; the result is to fit the data  
506 perfectly.

507

508 Having optimised parameters, each model was assessed using BIC. Variants for which a model  
509 of constant or time-dependent frequency is favoured over the neutral model are identified as  
510 potentially selected variants.

511

512 *Unconstrained haplotype reconstruction*

513

514 Unconstrained haplotype reconstruction was carried out using a modified version of the code  
515 designed for this purpose in the VeTrans software package (Ghafari et al., 2020), extended to  
516 consider more than two samples. Given multi-locus sequence data spanning the potentially  
517 selected loci, this identified the optimum haplotype reconstruction (measured according to a

518 likelihood fit to the data and using BIC to constrain the number of haplotypes). VeTrans is  
519 available online at [www.github.com/cjri/VeTrans](http://www.github.com/cjri/VeTrans).

520

521 *Haplotype selection model*

522

523 A constrained haplotype reconstruction was carried out using the Hapsel software package  
524 (<https://github.com/cjri/Hapsel>). Given multi-locus data describing changes in a population over  
525 time, plus a set of haplotype sequences  $H$ , this identifies optimal initial frequencies  $q_h(0)$  and  
526 selection coefficients  $s_h$  for these haplotypes so that the evolution of the haplotype frequencies  
527 under a deterministic model best fits the observed data.

528

529 *Materials availability*

530

531 Viral sequence data are available from the Sequence Read Archive with accession number  
532 PRJNA846693. Code used for the inference of parameters and for evolutionary simulation is  
533 available at <https://github.com/cjri/RSVMutationalLoad>. The VeTrans software package is  
534 available at <https://github.com/cjri/VeTrans>. The Hapsel software package is available at  
535 <https://github.com/cjri/Hapsel>.

536

537

538 *Ethics*

539

540 Approval for use of the residual diagnostic specimens was obtained through the UCL/UCLH  
541 Pathogen Biobank National Research Ethics Service Committee London Fulham (Research  
542 Ethics Committee reference: 12/LO/1089).

543

544 *Acknowledgements*


545

546 CJRI acknowledges UKRI Medical Research Council funding (MC\_UU\_12014). AYK is  
547 supported by the Wellcome Trust (222096/Z/20/Z). This work was supported in part by a Sir Henry  
548 Dale Fellowship, jointly funded by the Wellcome Trust and the Royal Society (grant numbers  
549 101239/Z/13/Z and 101239/Z/13/A). We thank the patient, their family and the medical teams  
550 involved in their care.

551

552

553 **Figures**




554

555 **Figure 1: Changes in viral load and CD3 cell count during RSV infection within an**  
556 **immunocompromised child.** Recovery from infection corresponded to a recovery in T-cell  
557 immunity. Black dots show CT scores and cell count data. A vertical black dashed line shows  
558 the time at which the child received an HSCT. Shading shows times of treatment with ribavirin,  
559 nitazoxanide, and favipiravir.

560



561



562

563 **Figure 2: Models describing changes in mutational load over time following treatment.**

564 Black dots show the measured mutational load in the viral population in samples collected over


565 time. Red lines show the maximum likelihood fit of each model to the data. Models fitted to the

566 data either allow or disallow favipiravir to have an independent effect on the viral mutation rate.

567 A lower BIC indicates a better fit between the model and the data, accounting for the complexity

568 of the model.

569



570

571

572 **Figure 2S1: Changes in genetic distance measurements with time show little signal of**

573 **consistent evolutionary change. A.** Measurements of the total genetic distance between

574 samples plotted against the difference in time between samples. The dashed blue line shows a

575 best fit regression line to the data, with the shaded region showing a 95% confidence interval.

576 The data show negligible evidence of more temporally separated samples being more

577 genetically distinct from one another, suggesting an evolutionarily stable population. Such

578 stability could arise either from a very large effective population size, or from evolutionary

579 constraint, for example if all possible changes to the genetic composition of the population led to

580 a substantial loss in population fitness. The value of the regression model at zero shows the

581 nominal level of 'noise' in the sequencing process, representing the combined effects of


582 unrepresentative sampling of a structured viral population plus errors induced in the processing

583 and sequencing of samples. **B.** A repeat analysis, measuring the Hamming distance between

584 consensus sequences, shows a similar result. The measure of genetic distance used in this

585 case is less susceptible to 'noise'.

586



587

588

589 **Figure 3: Mutational spectra as a function of mutational class. A.** Breakdown of mutational


590 load by mutational class. Background shading shows times of treatment with ribavirin,

591 nitazoxanide, and favipiravir. **B.** Proportion of mutational load comprised of each mutational

592 class in the first three (Before treatment) and last three (End of treatment) samples. Treatment

593 increased the proportion of C to T and G to A mutations.

594



595

596

597 **Figure 4: Effect of mutational load upon viral fitness.** **A.** Near-identical fits to the mutational

598 load data can be generated at different assumed viral generation times, with differences in the

599 visualised curves arising only from interpolation effects. Background shading shows times of

600 treatment with ribavirin, nitazoxanide, and favipiravir. **B.** Changes in the relative fitness of the


601 virus are strongly dependent upon the assumed generation time. **C.** The fate of the viral

602 population given treatment depends upon the assumed generation time and the fecundity of the

603 viral population prior to treatment. Shading shows parameters which lead to the clearance of

604 infection (blue) or the failure of treatment to clear infection (red), the latter corresponding to the

605 clinical observations. Squares with highlighted borders correspond to specific sets of  
606 parameters chosen for further analysis. **D.** Expected changes in viral load given these specific  
607 parameters, generated by a simple birth-death model with a carrying capacity. Within the  
608 model, treatment begins on day 15.  
609



610

611

612 **Figure 4S1: Changes in viral mutation rate and fitness under treatment. A.** Intrinsic rates


613 of RSV mutation inferred prior to and during treatment with ribavirin, expressed in units of

614 mutations per genome per generation, as a function of the viral generation time in hours. **B.**

615 Fold-drop in viral fitness as a function of the viral generation time. A drop of 10 is equivalent to

616 a reduction to one tenth of the previous fitness.

617




618

619

620 **Figure 5: Within-host variation.** **A.** Allele frequency trajectories of all variants that were  
 621 observed at a frequency of at least 5% in at least two samples. Trajectories are shown in gray  
 622 with potentially selected variants in colour. Background shading shows times of treatment with  
 623 ribavirin, nitazoxanide, and favipiravir. **B.** Evolutionarily constrained haplotype reconstruction,  
 624 in which each haplotype maintains a constant fitness over time. Not all of the haplotypes reach  
 625 frequencies sufficient to be observed in the plot. **C.** Genetic relationships between haplotypes

626 and inferred fitnesses. A solid line indicates haplotypes that are separated by a single mutation  
627 while a dashed line indicates haplotypes that are separated by two mutations.  
628





629

630

631 **Figure 5S1: Correlations between potentially selected variants.** Correlations between allele

632 frequencies for SNPs identified as being potentially influenced by selection. Statistics show the

633  $R^2$  value from a linear regression calculation, and the p-value for a correlation test conducted

634 using a Spearman Rank Correlation test. The pattern of frequencies is consistent with the


635 substitution H22Q and a synonymous SNP hitchhiking with F168Y, the latter being observed at

636 higher frequencies. Correlations shown between variants were significant at the  $p=0.05$  level

637 after Bonferroni correction. All such correlations occurred between SNPs within the RSV

638 attachment glycoprotein.

639




640

641

642 **Figure 5S2: Structure of the conserved region of the G protein.** The G protein is shown in  
643 gray ribbons, with the heavy and light chains of a neutralising antibody shown in blue and red.  
644 The F168Y substitution would introduce a hydroxyl group into the interface between G and the  
645 antibody, potentially disrupting antibody binding.

646



647

648

**Figure 5S3: Unconstrained haplotype reconstruction describing the inferred**

649

**relationships between potentially selected variants.** Haplotype reconstruction was

650

performed using multi-locus data from the seven loci at which potentially-selected variants were


651

identified. A total of 12 haplotypes were sufficient to explain the observed sequence data

652

across the potentially selected variant positions.

653



654

655

656 **Figure 6: Reconstruction of viral fitness over time.** **A.** Changes in the relative fitness of the  
657 viral population inferred according to our model of mutational load, under the conservative  
658 assumption of a viral generation time of 6 hours. Background shading shows times of treatment  
659 with ribavirin, nitazoxanide, and favipiravir. **B.** Changes in the relative fitness of the viral  
660 population inferred under our model of haplotype-based evolution. **C.** A combined model of  
661 fitness combines fitness components from both models in a multiplicative manner, showing the  
662 gain of fitness due to adaptive evolution in combination with the inferred loss of fitness through  
663 the gain of deleterious mutations arising through viral mutagenesis. We note that, even under a  
664 conservative model of the effects of viral load, adaptive evolution does not compensate for the  
665 increase in mutational load.

666

667 **Supporting Table 1:** Details of variant frequencies for all variants which reached a minor allele  
668 frequency of at least 5% in at least two samples. We report numbers of each nucleotide  
669 observed at each locus containing such a variant, for all time samples.

670 **References**

671

672 Abdelnabi R, Foo CS, Kaptein SJF, Zhang X, Do TND, Langendries L, Vangeel L, Breuer J,  
673 Pang J, Williams R, Vergote V, Heylen E, Leyssen P, Dallmeier K, Coelmont L, Chatterjee  
674 AK, Mols R, Augustijns P, De Jonghe S, Jochmans D, Weynand B, Neyts J. 2021. The  
675 combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral  
676 efficacy in a SARS-CoV-2 hamster infection model. *eBioMedicine*.  
677 doi:10.1016/j.ebiom.2021.103595

678 Adams R, Christenson J, Petersen F, Beatty P. 1999. Pre-emptive use of aerosolized ribavirin in  
679 the treatment of asymptomatic pediatric marrow transplant patients testing positive for RSV.  
680 *Bone Marrow Transplant* **24**:661–664.

681 Baccam P, Beauchemin C, Macken CA, Hayden FG, Perelson AS. 2006. Kinetics of influenza A  
682 virus infection in humans. *J Virol* **80**:7590–7599.

683 Blum VF, Cimerman S, Hunter JR, Tierno P, Lacerda A, Soeiro A, Cardoso F, Bellei NC,  
684 Maricato J, Mantovani N, Vassao M, Dias D, Galinskas J, Janini LMR, Santos-Oliveira JR,  
685 Da-Cruz AM, Diaz RS. 2021. Nitazoxanide superiority to placebo to treat moderate COVID-  
686 19 - A Pilot prove of concept randomized double-blind clinical trial. *EClinicalMedicine*  
687 **37**:100981.

688 Britton PN, Hu N, Saravanos G, Shrapnel J, Davis J, Snelling T, Dalby-Payne J, Kesson AM,  
689 Wood N, Macartney K, McCullagh C, Lingam R. 2020. COVID-19 public health measures  
690 and respiratory syncytial virus. *The Lancet Child & Adolescent Health*. doi:10.1016/s2352-  
691 4642(20)30307-2

692 Brown L-AK, Freemantle N, Breuer J, Dehbi H-M, Chowdhury K, Jones G, Ikeji F, Ndoutoumou  
693 A, Santhirakumar K, Longley N, Checkley AM, Standing JF, Lowe DM. 2021. Early antiviral  
694 treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol

- 695 for a randomised controlled trial. *Trials* **22**:193.
- 696 Bull JJ, Sanjuán R, Wilke CO. 2007. Theory of lethal mutagenesis for viruses. *J Virol* **81**:2930–  
697 2939.
- 698 Depledge DP, Palser AL, Watson SJ, Lai IY-C, Gray ER, Grant P, Kanda RK, Leproust E,  
699 Kellam P, Breuer J. 2011. Specific capture and whole-genome sequencing of viruses from  
700 clinical samples. *PLoS One* **6**:e27805.
- 701 de Visser JAGM, Krug J. 2014. Empirical fitness landscapes and the predictability of evolution.  
702 *Nat Rev Genet* **15**:480–490.
- 703 Domachowske JB, Anderson EJ, Goldstein M. 2021. The Future of Respiratory Syncytial Virus  
704 Disease Prevention and Treatment. *Infect Dis Ther* **10**:47–60.
- 705 Franco EJ, Warfield KL, Brown AN. 2022. UV-4B potently inhibits replication of multiple SARS-  
706 CoV-2 strains in clinically relevant human cell lines. *Front Biosci* **27**:3.
- 707 Furuta Y, Komeno T, Nakamura T. 2017. Favipiravir (T-705), a broad spectrum inhibitor of viral  
708 RNA polymerase. *Proc Jpn Acad Ser B Phys Biol Sci* **93**:449–463.
- 709 Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, Nomura N, Egawa H,  
710 Minami S, Watanabe Y, Narita H, Shiraki K. 2002. In Vitro and In Vivo Activities of Anti-  
711 Influenza Virus Compound T-705. *Antimicrobial Agents and Chemotherapy*.  
712 doi:10.1128/aac.46.4.977-981.2002
- 713 Ghafari M, Lumby CK, Weissman DB, Illingworth CJR. 2020. Inferring Transmission Bottleneck  
714 Size from Viral Sequence Data Using a Novel Haplotype Reconstruction Method. *J Virol* **94**.  
715 doi:10.1128/JVI.00014-20
- 716 Ginsburg AS, Srikantiah P. 2021. Respiratory syncytial virus: promising progress against a  
717 leading cause of pneumonia. *Lancet Glob Health* **9**:e1644–e1645.
- 718 Goldhill DH, Langat P, Xie H, Galiano M, Miah S, Kellam P, Zambon M, Lackenby A, Barclay  
719 WS. 2019. Determining the Mutation Bias of Favipiravir in Influenza Virus Using Next-  
720 Generation Sequencing. *J Virol* **93**. doi:10.1128/JVI.01217-18

- 721 Goldhill DH, Te Velthuis AJW, Fletcher RA, Langat P, Zambon M, Lackenby A, Barclay WS.  
722 2018. The mechanism of resistance to favipiravir in influenza. *Proc Natl Acad Sci U S A*  
723 **115**:11613–11618.
- 724 Gordon CJ, Tchesnokov EP, Schinazi RF, Götte M. 2021. Molnupiravir promotes SARS-CoV-2  
725 mutagenesis via the RNA template. *J Biol Chem* **297**:100770.
- 726 Guedj J, Piorkowski G, Jacquot F, Madelain V, Nguyen THT, Rodallec A, Gunther S,  
727 Carbonnelle C, Mentré F, Raoul H, de Lamballerie X. 2018. Antiviral efficacy of favipiravir  
728 against Ebola virus: A translational study in cynomolgus macaques. *PLoS Med*  
729 **15**:e1002535.
- 730 Haldane JBS. 1937. The Effect of Variation of Fitness. *The American Naturalist*.  
731 doi:10.1086/280722
- 732 Hall CB, McBride JT, Walsh EE, Bell DM, Gala CL, Hildreth S, Ten Eyck LG, Hall WJ. 1983.  
733 Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A  
734 randomized double-blind study. *N Engl J Med* **308**:1443–1447.
- 735 Harari S, Tahor M, Rutsinsky N, Meijer S, Miller D, Henig O, Halutz O, Levytskyi K, Ben-Ami R,  
736 Adler A, Paran Y, Stern A. 2022. Drivers of adaptive evolution during chronic SARS-CoV-2  
737 infections. *Nat Med* **28**:1501–1508.
- 738 Hatter L, Eathorne A, Hills T, Bruce P, Beasley R. 2021. Respiratory syncytial virus: paying the  
739 immunity debt with interest. *Lancet Child Adolesc Health* **5**:e44–e45.
- 740 Hayden FG, Lenk RP, Stonis L, Oldham-Creamer C, Kang LL, Epstein C. 2022. Favipiravir  
741 Treatment of Uncomplicated Influenza in Adults: Results of Two Phase 3, Randomized,  
742 Double-Blind, Placebo-Controlled Trials. *J Infect Dis*. doi:10.1093/infdis/jjac135
- 743 Hirsch HH, Martino R, Ward KN, Boeckh M, Einsele H, Ljungman P. 2013. Fourth European  
744 Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of  
745 human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and  
746 coronavirus. *Clin Infect Dis* **56**:258–266.



- 747 Illingworth CJR. 2016. SAMFIRE: multi-locus variant calling for time-resolved sequence data.  
748 *Bioinformatics* **32**:2208–2209.
- 749 Illingworth CJR. 2015. Fitness Inference from Short-Read Data: Within-Host Evolution of a  
750 Reassortant H5N1 Influenza Virus. *Mol Biol Evol* **32**:3012–3026.
- 751 Illingworth CJR, Mustonen V. 2012. Components of selection in the evolution of the influenza  
752 virus: linkage effects beat inherent selection. *PLoS Pathog* **8**:e1003091.
- 753 Jasenosky LD, Cadena C, Mire CE, Borisevich V, Haridas V, Ranjbar S, Nambu A, Bavari S,  
754 Soloveva V, Sadukhan S, Cassell GH, Geisbert TW, Hur S, Goldfeld AE. 2019. The FDA-  
755 Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola  
756 Virus. *iScience*. doi:10.1016/j.isci.2019.07.003
- 757 Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V,  
758 Martín-Quirós A, Caraco Y, Williams-Diaz A, Brown ML, Du J, Pedley A, Assaid C, Strizki J,  
759 Grobler JA, Shamsuddin HH, Tipping R, Wan H, Paschke A, Butterson JR, Johnson MG,  
760 De Anda C, MOVE-OUT Study Group. 2022. Molnupiravir for Oral Treatment of Covid-19 in  
761 Nonhospitalized Patients. *N Engl J Med* **386**:509–520.
- 762 Jones HG, Ritschel T, Pascual G, Brakenhoff JPJ, Keogh E, Furmanova-Hollenstein P,  
763 Lanckacker E, Wadia JS, Gilman MSA, Williamson RA, Roymans D, van 't Wout AB,  
764 Langedijk JP, McLellan JS. 2018. Structural basis for recognition of the central conserved  
765 region of RSV G by neutralizing human antibodies. *PLoS Pathog* **14**:e1006935.
- 766 Kabinger F, Stiller C, Schmitzova J, Dienemann C, Kokic G, Hillen HS, Hoebartner C, Cramer  
767 P. 2021. SARS-CoV-2 RdRp with Molnupiravir/ NHC in the template strand base-paired  
768 with A. doi:10.2210/pdb7ozu/pdb
- 769 Kaptein SJF, Jacobs S, Langendries L, Seldeslachts L, Ter Horst S, Liesenborghs L, Hens B,  
770 Vergote V, Heylen E, Barthelemy K, Maas E, De Keyzer C, Bervoets L, Rymenants J, Van  
771 Buyten T, Zhang X, Abdelnabi R, Pang J, Williams R, Thibaut HJ, Dallmeier K, Boudewijns  
772 R, Wouters J, Augustijns P, Verougstraete N, Cawthorne C, Breuer J, Solas C, Weynand B,

773 Annaert P, Spriet I, Vande Velde G, Neyts J, Rocha-Pereira J, Delang L. 2020. Favipiravir  
774 at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas  
775 hydroxychloroquine lacks activity. *Proc Natl Acad Sci U S A* **117**:26955–26965.

776 Kemp SA, Collier DA, Datir RP, Ferreira IATM, Gayed S, Jahun A, Hosmillo M, Rees-Spear C,  
777 Mlcochova P, Lumb IU, Roberts DJ, Chandra A, Temperton N, CITIID-NIHR BioResource  
778 COVID-19 Collaboration, COVID-19 Genomics UK (COG-UK) Consortium, Sharrocks K,  
779 Blane E, Modis Y, Leigh KE, Briggs JAG, van Gils MJ, Smith KGC, Bradley JR, Smith C,  
780 Doffinger R, Ceron-Gutierrez L, Barcenas-Morales G, Pollock DD, Goldstein RA,  
781 Smielewska A, Skittrall JP, Gouliouris T, Goodfellow IG, Gkrania-Klotsas E, Illingworth  
782 CJR, McCoy LE, Gupta RK. 2021. SARS-CoV-2 evolution during treatment of chronic  
783 infection. *Nature* **592**:277–282.

784 Koelle K, Rasmussen DA. 2015. The effects of a deleterious mutation load on patterns of  
785 influenza A/H3N2's antigenic evolution in humans. *Elife* **4**:e07361.

786 Li H, Durbin R. 2010. Fast and accurate long-read alignment with Burrows-Wheeler transform.  
787 *Bioinformatics* **26**:589–595.

788 Lumby CK, Nene NR, Illingworth CJR. 2018. A novel framework for inferring parameters of  
789 transmission from viral sequence data. *PLoS Genet* **14**:e1007718.

790 Lumby CK, Zhao L, Breuer J, Illingworth C Jr. 2020a. A large effective population size for  
791 established within-host influenza virus infection. *Elife* **9**. doi:10.7554/eLife.56915

792 Lumby CK, Zhao L, Oporto M, Best T, Tutill H, Shah D, Veys P, Williams R, Worth A, Illingworth  
793 CJR, Breuer J. 2020b. Favipiravir and Zanamivir Cleared Infection with Influenza B in a  
794 Severely Immunocompromised Child. *Clin Infect Dis* **71**:e191–e194.

795 Madhi SA, Polack FP, Piedra PA, Munoz FM, Trenholme AA, Simões EAF, Swamy GK,  
796 Agrawal S, Ahmed K, August A, Baqui AH, Calvert A, Chen J, Cho I, Cotton MF, Cutland  
797 CL, Englund JA, Fix A, Gonik B, Hammitt L, Heath PT, de Jesus JN, Jones CE, Khalil A,  
798 Kimberlin DW, Libster R, Llapur CJ, Lucero M, Pérez Marc G, Marshall HS, Masenya MS,

799 Martín-Torres F, Meece JK, Nolan TM, Osman A, Perrett KP, Plested JS, Richmond PC,  
800 Snape MD, Shakib JH, Shinde V, Stoney T, Thomas DN, Tita AT, Varner MW, Vatish M,  
801 Vrbicky K, Wen J, Zaman K, Zar HJ, Glenn GM, Fries LF, Prepare Study Group. 2020.  
802 Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants. *N Engl J*  
803 *Med* **383**:426–439.

804 McLellan JS, Ray WC, Peeples ME. 2013. Structure and function of respiratory syncytial virus  
805 surface glycoproteins. *Curr Top Microbiol Immunol* **372**:83–104.

806 Mejias A, Ramilo. 2008. Review of palivizumab in the prophylaxis of respiratory syncytial virus  
807 (RSV) in high-risk infants. *Biologics: Targets & Therapy*. doi:10.2147/btt.s3104

808 Morris SK, Dzolganovski B, Beyene J, Sung L. 2009. A meta-analysis of the effect of antibody  
809 therapy for the prevention of severe respiratory syncytial virus infection. *BMC Infect Dis*  
810 **9**:106.

811 O'Brien KL, Chandran A, Weatherholtz R, Jafri HS, Griffin MP, Bellamy T, Millar EV, Jensen  
812 KM, Harris BS, Reid R, Moulton LH, Losonsky GA, Karron RA, Santosham M, Respiratory  
813 Syncytial Virus (RSV) Prevention study group. 2015. Efficacy of motavizumab for the  
814 prevention of respiratory syncytial virus disease in healthy Native American infants: a phase  
815 3 randomised double-blind placebo-controlled trial. *Lancet Infect Dis* **15**:1398–1408.

816 Ottaviano G, Lucchini G, Breuer J, Furtado-Silva JM, Lazareva A, Ciocarlie O, Elfeky R, Rao K,  
817 Amrolia PJ, Veys P, Chiesa R. 2020. Delaying haematopoietic stem cell transplantation in  
818 children with viral respiratory infections reduces transplant-related mortality. *Br J Haematol*  
819 **188**:560–569.

820 Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. 1996. HIV-1 dynamics in vivo:  
821 virion clearance rate, infected cell life-span, and viral generation time. *Science* **271**:1582–  
822 1586.

823 Raghwani J, Rose R, Sheridan I, Lemey P, Suchard MA, Santantonio T, Farci P, Klenerman P,  
824 Pybus OG. 2016. Exceptional Heterogeneity in Viral Evolutionary Dynamics Characterises

825           Chronic Hepatitis C Virus Infection. *PLoS Pathog* **12**:e1005894.

826   Ruis C, Brown L-AK, Roy S, Atkinson C, Williams R, Burns SO, Yara-Romero E, Jacobs M,  
827           Goldstein R, Breuer J, Lowe DM. 2018. Mutagenesis in Norovirus in Response to  
828           Favipiravir Treatment. *N Engl J Med* **379**:2173–2176.

829   Schiffels S, Szöllosi GJ, Mustonen V, Lässig M. 2011. Emergent neutrality in adaptive asexual  
830           evolution. *Genetics* **189**:1361–1375.

831   Schwarz G. 1978. Estimating the Dimension of a Model. *The Annals of Statistics*.  
832           doi:10.1214/aos/1176344136

833   Shi T, McAllister DA, O'Brien KL, Simoes EAF, Madhi SA, Gessner BD, Polack FP, Balsells E,  
834           Acacio S, Aguayo C, Alassani I, Ali A, Antonio M, Awasthi S, Awori JO, Azziz-Baumgartner  
835           E, Baggett HC, Baillie VL, Balmaseda A, Barahona A, Basnet S, Bassat Q, Basualdo W,  
836           Bigogo G, Bont L, Breiman RF, Brooks WA, Broor S, Bruce N, Bruden D, Buchy P,  
837           Campbell S, Carosone-Link P, Chadha M, Chipeta J, Chou M, Clara W, Cohen C, de  
838           Cuellar E, Dang D-A, Dash-Yandag B, Deloria-Knoll M, Dherani M, Eap T, Ebruke BE,  
839           Echavarria M, de Freitas Lázaro Emediato CC, Fasce RA, Feikin DR, Feng L, Gentile A,  
840           Gordon A, Goswami D, Goyet S, Groome M, Halasa N, Hirve S, Homaira N, Howie SRC,  
841           Jara J, Jroundi I, Kartasasmita CB, Khuri-Bulos N, Kotloff KL, Krishnan A, Libster R, Lopez  
842           O, Lucero MG, Lucion F, Lupisan SP, Marcone DN, McCracken JP, Mejia M, Moisi JC,  
843           Montgomery JM, Moore DP, Moraleta C, Moyes J, Munywoki P, Mutyara K, Nicol MP,  
844           Nokes DJ, Nymadawa P, da Costa Oliveira MT, Oshitani H, Pandey N, Paranhos-Baccalà  
845           G, Phillips LN, Picot VS, Rahman M, Rakoto-Andrianarivelo M, Rasmussen ZA, Rath BA,  
846           Robinson A, Romero C, Russomando G, Salimi V, Sawatwong P, Scheltema N, Schweiger  
847           B, Scott JAG, Seidenberg P, Shen K, Singleton R, Sotomayor V, Strand TA, Sutanto A,  
848           Sylla M, Tapia MD, Thamthitiwat S, Thomas ED, Tokarz R, Turner C, Venter M,  
849           Waicharoen S, Wang J, Watthanaworawit W, Yoshida L-M, Yu H, Zar HJ, Campbell H, Nair  
850           H, RSV Global Epidemiology Network. 2017. Global, regional, and national disease burden

851 estimates of acute lower respiratory infections due to respiratory syncytial virus in young  
852 children in 2015: a systematic review and modelling study. *Lancet* **390**:946–958.

853 Sobel Leonard A, McClain MT, Smith GJD, Wentworth DE, Halpin RA, Lin X, Ransier A,  
854 Stockwell TB, Das SR, Gilbert AS, Lambkin-Williams R, Ginsburg GS, Woods CW, Koelle  
855 K, Illingworth CJR. 2017. The effective rate of influenza reassortment is limited during  
856 human infection. *PLoS Pathog* **13**:e1006203.

857 Sparrelid E, Ljungman P, Ekelöf-Andström E, Aschan J, Ringdén O, Winiarski J, Wåhlin B,  
858 Andersson J. 1997. Ribavirin therapy in bone marrow transplant recipients with viral  
859 respiratory tract infections. *Bone Marrow Transplant* **19**:905–908.

860 Swanson KA, Settembre EC, Shaw CA, Dey AK, Rappuoli R, Mandl CW, Dormitzer PR, Carfi A.  
861 2011. Structural basis for immunization with postfusion respiratory syncytial virus fusion F  
862 glycoprotein (RSV F) to elicit high neutralizing antibody titers. *Proc Natl Acad Sci U S A*  
863 **108**:9619–9624.

864 Swanstrom R, Schinazi RF. 2022. Lethal mutagenesis as an antiviral strategy. *Science*  
865 **375**:497–498.

866 Turner TL, Kopp BT, Paul G, Landgrave LC, Hayes D Jr, Thompson R. 2014. Respiratory  
867 syncytial virus: current and emerging treatment options. *Clinicoecon Outcomes Res* **6**:217–  
868 225.

869 Vanderlinden E, Vrancken B, Van Houdt J, Rajwanshi VK, Gillemot S, Andrei G, Lemey P,  
870 Naesens L. 2016. Distinct Effects of T-705 (Favipiravir) and Ribavirin on Influenza Virus  
871 Replication and Viral RNA Synthesis. *Antimicrobial Agents and Chemotherapy*.  
872 doi:10.1128/aac.01156-16

873 van Summeren J, Meijer A, Aspelund G, Casalegno JS, Erna G, Hoang U, Lina B, VRS study  
874 group in Lyon, de Lusignan S, Teirlinck AC, Thors V, Paget J. 2021. Low levels of  
875 respiratory syncytial virus activity in Europe during the 2020/21 season: what can we  
876 expect in the coming summer and autumn/winter? *Euro Surveill* **26**. doi:10.2807/1560-

877 7917.ES.2021.26.29.2100639

878 Vo NV, Young K-C, Lai MMC. 2003. Mutagenic and inhibitory effects of ribavirin on hepatitis C  
879 virus RNA polymerase. *Biochemistry* **42**:10462–10471.

880 Wang Y, Fan G, Salam A, Horby P, Hayden FG, Chen C, Pan J, Zheng J, Lu B, Guo L, Wang  
881 C, Cao B. 2020a. Comparative Effectiveness of Combined Favipiravir and Oseltamivir  
882 Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus  
883 Infection. *The Journal of Infectious Diseases*. doi:10.1093/infdis/jiz656

884 Wang Y, Zhong W, Salam A, Tarning J, Zhan Q, Huang J-A, Weng H, Bai C, Ren Y, Yamada K,  
885 Wang D, Guo Q, Fang Q, Tsutomu S, Zou X, Li H, Gillesen A, Castle L, Chen C, Li H, Zhen  
886 J, Lu B, Duan J, Guo L, Jiang J, Cao R, Fan G, Li J, Hayden FG, Wang C, Horby P, Cao B.  
887 2020b. Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of  
888 favipiravir (T-705) in combination with oseltamivir in patients with severe influenza.  
889 *EBioMedicine* **62**:103125.

890 Wegzyn C, Toh LK, Notario G, Biguenet S, Unnebrink K, Park C, Makari D, Norton M. 2014.  
891 Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to  
892 Respiratory Syncytial Virus Infection: A Systematic Review. *Infect Dis Ther* **3**:133–158.

893 Zhao X, Chen F-P, Sullender WM. 2004. Respiratory syncytial virus escape mutant derived in  
894 vitro resists palivizumab prophylaxis in cotton rats. *Virology* **318**:608–612.

895